에 대한 최신 뉴스 Algonquin Power (NYSE:AQN) 주식

Algonquin Power

Algonquin Power & Utilities Corp is a Canada-based diversified international generation, transmission, and distribution company. The company's operations are organized across two business units consisting of the Regulated Services Group, which owns and operates a portfolio of regulated electric, water distribution and wastewater collection, and natural gas utility systems and transmission operations in the United States, Canada, Bermuda, and Chile; and the Hydro Group, which consists of hydroelectric-generating facilities located in Canada. It generates the majority of its revenue from the Regulated Services Group segment.

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

목요일(6일) CNN 머니 공포·탐욕 지수는 &#34;극단적 공포&#34; 영역에 머물렀다.미국 증시는 목요일에 하락세로 마감했다. 다우존스 지수는 세션 중에 400포인트 이상 하락했다. 이는 미국이 캐나다, 멕시코, 중국 수입품에 관세를 부과하고 무역 파트너들이 미국 상품에 보복관세를 부과한 영향으로 나타났다.

트럼프 관세로 다우 지수 400p 하락: 탐욕 지수는 &#39;극단적 공포&#39; 유지

BroadcomSeptember,9,,2019,Sunnyvale, - ,Ca, - ,Usa,-,Broadcom

AVGO

SWBI

금요일(7일) 아침 미국 주식 선물이 상승하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 몇 가지 주식은 다음과 같다. 브로드컴, 알곤퀸 파워, 제네스코, 스미스 앤 웨슨 및 어드밴티지 솔루션스

금요일 주목해야 할 주식: 브로드컴, 알곤퀸 파워, 제네스코, 스미스 앤 웨슨 및 어드밴티지 솔루션스

Algonquin Power & Utilities Corp. Common Shares

Algonquin Power & Utilities Corp

Algonquin Power & Utilities Corp 6.875% Fxd/Fltg Sub Nts Ser 2018-A 10/17/2078

Algonquin Power & Utilities Corp. 6.20% Fixed-to-Floating Subordinated Notes Series 2019-A due July 1, 2079

Algonquin Power & Utilities Corp 7.75% Corp Unit 06/15/2024

Alaris Equity Partners (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AD#TSX">AD</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.40 by 25 percent. This is a 67.11 percent decrease over earnings of $1.52 per share from the same period last year. The company reported quarterly sales of $36.39 million which missed the analyst consensus estimate of $43.82 million by 16.96 percent. This is a 23.28 percent decrease over sales of $47.43 million the same period last year.

Earnings Beats

Earnings Misses

TSX:AD

Alaris Equity Partners Q1 EPS $0.50 Beats $0.40 Estimate, Sales $36.39M Miss $43.82M Estimate

Atlanticus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATLC#NASDAQ">ATLC</a>) reported quarterly earnings of $1.49 per share which beat the analyst consensus estimate of $1.48 by 0.68 percent. This is a 36.7 percent increase over earnings of $1.09 per share from the same period last year. The company reported quarterly sales of $344.87 million which missed the analyst consensus estimate of $347.24 million by 0.68 percent. This is a 18.63 percent increase over sales of $290.71 million the same period last year.

ATLC

Atlanticus Holdings Q1 EPS $1.49 Beats $1.48 Estimate, Sales $344.87M Miss $347.24M Estimate

Turnstone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.26) by 96.15 percent. This is a 40 percent increase over losses of $(0.85) per share from the same period last year.

TSBX

Turnstone Biologics Q1 EPS $(0.51) Misses $(0.26) Estimate

Doman Building Materials (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DBM#TSX">DBM</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.12 by 125 percent. This is a 68.75 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $793.20 million which beat the analyst consensus estimate of $757.38 million by 4.73 percent. This is a 31.66 percent increase over sales of $602.48 million the same period last year.

TSX:DBM

Doman Building Materials Q1 Adj. EPS $0.27 Beats $0.12 Estimate, Sales $793.20M Beat $757.38M Estimate

Guidance

NNBR

CORRECTION: NN Lowers FY2025 Sales Guidance To $430.00M-$460.00M vs $454.30M Est

Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) affirms FY2025 Adj EPS guidance from $6.64-$7.28 to $6.64-$7.28 vs $6.97 analyst estimate. Affirms FY2025 sales outlook from $1.44 billion-$1.50 billion to $1.44 billion-$1.50 billion vs $1.46 billion estimate.

Ziff Davis Affirms FY2025 Adj EPS Guidance of $6.64-$7.28 vs $6.97 Est; Affirms FY2025 Sales Guidance of $1.44B-$1.50B vs $1.46B Est

Karat Packaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>) affirms FY2025 sales outlook from $460.67 million-$469.12 million to $460.67 million-$469.12 million vs $461.42 million estimate.

Karat Packaging Reiterating FY2025 guidance on net sales, gross margin and adjusted EBITDA margin.

Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) reported quarterly earnings of $1.14 per share which missed the analyst consensus estimate of $1.25 by 8.8 percent. This is a 10.24 percent decrease over earnings of $1.27 per share from the same period last year. The company reported quarterly sales of $328.64 million which beat the analyst consensus estimate of $324.19 million by 1.37 percent. This is a 4.50 percent increase over sales of $314.49 million the same period last year.

Ziff Davis Q1 Adj. EPS $1.14 Misses $1.25 Estimate, Sales $328.64M Beat $324.19M Estimate

Canacol Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNE#TSX">CNE</a>) reported quarterly earnings of $0.93 per share. This is a 745.45 percent increase over earnings of $0.11 per share from the same period last year. The company reported $72.73 million in sales this quarter. This is a 6.38 percent decrease over sales of $77.69 million the same period last year.

TSX:CNE

Canacol Energy Q1 EPS $0.93 Up From $0.11 YoY, Sales $72.73M Down From $77.69M YoY

Across the recent three months, 4 analysts have shared their insights on Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $8.25, with a high estimate of $9.00 and a low estimate of $8.00. Holding firm without variation, the current average remains at the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1746741664_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Generation Bio by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Generation Bio. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Generation Bio compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Generation Bio's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Generation Bio's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GBIO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Generation Bio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Generation Bio</h2>
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
<h3>Unraveling the Financial Story of Generation Bio</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Generation Bio's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 45.52% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Generation Bio's net margin excels beyond industry benchmarks, reaching -510.55%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Generation Bio's ROE excels beyond industry benchmarks, reaching -22.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Generation Bio's ROA excels beyond industry benchmarks, reaching -8.91%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.09, Generation Bio adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

GBIO

Where Generation Bio Stands With Analysts

10 analysts have expressed a variety of opinions on MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for MarketAxess Holdings, presenting an average target of $235.7, a high estimate of $295.00, and a low estimate of $191.00. Observing a 0.08% increase, the current average has risen from the previous average price target of $235.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1746741652_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of MarketAxess Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$265.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$240.00</td>
<td>$232.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$202.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$226.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$283.00</td>
<td>$263.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$213.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$295.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$232.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Eli Abboud</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$191.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$235.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MarketAxess Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of MarketAxess Holdings compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of MarketAxess Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into MarketAxess Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MKTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MarketAxess Holdings analyst ratings.</a>
<h2>Get to Know MarketAxess Holdings Better</h2>
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
<h3>Understanding the Numbers: MarketAxess Holdings's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: MarketAxess Holdings displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 2.61%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: MarketAxess Holdings's net margin excels beyond industry benchmarks, reaching 32.18%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): MarketAxess Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.69%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): MarketAxess Holdings's ROA excels beyond industry benchmarks, reaching 3.6%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.05, MarketAxess Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MKTX

The Analyst Verdict: MarketAxess Holdings In The Eyes Of 10 Experts

11 analysts have shared their evaluations of Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $170.82, along with a high estimate of $201.00 and a low estimate of $142.00. This current average has decreased by 9.18% from the previous average price target of $188.09. 
<img src="https://www.benzinga.com/files/images/story/2025/1746741643_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Ares Management by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$152.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$161.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$156.00</td>
<td>$187.00</td>
</tr>
<tr>
<td>Brian McKenna</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$165.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$142.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$201.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$166.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$187.00</td>
<td>$215.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ares Management. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ares Management compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Ares Management's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ares Management's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ARES/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ares Management analyst ratings.</a>
<h2>Get to Know Ares Management Better</h2>
Ares Management Corp is an asset management company. It offers investors investment-related advice and strategies for capital growth. The company's operating segments include Credit Group, Private Equity Group, Real Assets, Secondaries Group, and Others. Its Credit Group generates maximum revenue and manages credit strategies across the liquid and illiquid spectrum. Private Equity Group manages investment strategies categorized as corporate private equity, infrastructure and power, and special opportunities, Real Estate Group manages comprehensive equity and debt strategies across real estate &amp; infrastructure investments. The Secondaries Group invests in secondary markets across a range of alternative asset class strategies, including private equity, real estate, infrastructure, &amp; credit.
<h3>Unraveling the Financial Story of Ares Management</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Ares Management's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 19.45%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Ares Management's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -3.39%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.05%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Ares Management's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.17%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Ares Management's debt-to-equity ratio stands notably higher than the industry average, reaching 6.31. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARES

Assessing Ares Management: Insights From 11 Financial Analysts

i3 Verticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) lowers FY2025 Adj EPS guidance from $1.05-$1.25 to $0.96-$1.06 vs $1.17 analyst estimate. Lowers FY2025 sales outlook from $243.00 million-$263.00 million to $207.00 million-$217.00 million vs $250.53 million estimate.

IIIV

i3 Verticals Lowers FY2025 Adj EPS Guidance from $1.05-$1.25 to $0.96-$1.06 vs $1.17 Est; Lowers FY2025 Sales Guidance from $243.00M-$263.00M to $207.00M-$217.00M vs $250.53M Est

In the preceding three months, 5 analysts have released ratings for CDW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $186.0, a high estimate of $210.00, and a low estimate of $160.00. A decline of 12.35% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1746741636_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of CDW's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asiya Merchant</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$180.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>David Vogt</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$210.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>George Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$205.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Asiya Merchant</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CDW. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CDW compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for CDW's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of CDW's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CDW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CDW analyst ratings.</a>
<h2>Get to Know CDW Better</h2>
CDW Corp is a multi-brand provider of information technology ("IT") solutions to small, medium, and large business, government, education, and healthcare customers in the United States, the United Kingdom, and Canada. The company's broad array of offerings ranges from discrete hardware and software products to integrated IT solutions and services that include on-premise and cloud capabilities across hybrid infrastructure, digital experience, and security. The company has five operating segments namely, Corporate, Small Business, Public, CDW UK, and CDW Canada. The Corporate segment generates the majority of its revenue and serves USA private sector business customers.
<h3>CDW's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: CDW displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 3.34%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: CDW's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.09% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): CDW's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.24% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.82%, the company showcases effective utilization of assets.
Debt Management: CDW's debt-to-equity ratio stands notably higher than the industry average, reaching 2.55. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CDW Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Looking into the current session, CPI Card Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) shares are trading at $19.85, after a 1.64% decrease. Over the past month, the stock fell by 6.29%, but over the past year, it actually went up by 0.96%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1746741627_0.png" alt="Past Year Chart" />

<h3>Evaluating CPI Card P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
CPI Card has a lower P/E than the aggregate P/E of 25.28 of the Technology Hardware, Storage &amp; Peripherals industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1746741628_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

PMTS

P/E Ratio Insights for CPI Card

During the last three months, 4 analysts shared their evaluations of Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $18.12, with a high estimate of $20.00 and a low estimate of $16.00. Surpassing the previous average price target of $17.12, the current average has increased by 5.84%.
<img src="https://www.benzinga.com/files/images/story/2025/1746741623_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Pediatrix Medical Group is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.50</td>
<td>$16.50</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pediatrix Medical Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pediatrix Medical Group compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Pediatrix Medical Group's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pediatrix Medical Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Pediatrix Medical Group: A Closer Look</h2>
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
<h3>Key Indicators: Pediatrix Medical Group's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Pediatrix Medical Group faced challenges, resulting in a decline of approximately -7.42% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.52%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Pediatrix Medical Group's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.67%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Pediatrix Medical Group's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.0%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Pediatrix Medical Group's debt-to-equity ratio is below the industry average. With a ratio of 0.83, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Pediatrix Medical Group Through The Eyes Of 4 Analysts

Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) has outperformed the market over the past 10 years by 3.0% on an annualized basis producing an average annual return of 13.4%. Currently, Martin Marietta Materials has a market capitalization of $33.02 billion. 
Buying $100 In MLM: If an investor had bought $100 of MLM stock 10 years ago, it would be worth $359.24 today based on a price of $541.56 for MLM at the time of writing.
<h3>Martin Marietta Materials's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746741617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Martin Marietta Materials 10 Years Ago Would Be Worth Today

10 analysts have expressed a variety of opinions on Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $28.4, along with a high estimate of $33.00 and a low estimate of $24.00. Witnessing a positive shift, the current average has risen by 5.19% from the previous average price target of $27.00.
<img src="https://www.benzinga.com/files/images/story/2025/1746741613_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Remitly Global is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Markgraff</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Philip Gibbs</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$24.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$32.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$29.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Remitly Global. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Remitly Global compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Remitly Global's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Remitly Global's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RELY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Remitly Global analyst ratings.</a>
<h2>All You Need to Know About Remitly Global</h2>
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
<h3>Financial Milestones: Remitly Global's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Remitly Global's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 32.91%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Remitly Global's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -1.63%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Remitly Global's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -0.88%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Remitly Global's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.58%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RELY

Analyst Expectations For Remitly Global's Future

FTAI Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIP#NASDAQ">FIP</a>) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.29) by 68.97 percent. This is a 83.33 percent increase over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $96.16 million which missed the analyst consensus estimate of $107.83 million by 10.82 percent. This is a 16.51 percent increase over sales of $82.53 million the same period last year.

FTAI Infrastructure Q1 Adj. EPS $(0.09) Beats $(0.29) Estimate, Sales $96.16M Miss $107.83M Estimate

i3 Verticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.30 by 6.67 percent. This is a 5.88 percent decrease over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $63.06 million which missed the analyst consensus estimate of $64.12 million by 1.66 percent. This is a 33.30 percent decrease over sales of $94.54 million the same period last year.

i3 Verticals Q2 Adj. EPS $0.32 Beats $0.30 Estimate, Sales $63.06M Miss $64.12M Estimate

Press Releases

Algonquin Power & Utilities Corp. Completes Sale of Renewable Energy Business to LS Power

Algonquin Power & Utilities Corp. Announces Upcoming Departure of Chief Financial Officer

Canadian Tire Corporation announces CFO transition

Algonquin Power & Utilities Corp. Announces Date for Fourth Quarter and Full Year 2024 Financial Results and Conference Call

Algonquin Power & Utilities Corp. Announces Leadership Transition

Algonquin Power & Utilities Corp. Announces Interim CFO Appointment

Algonquin Power & Utilities Corp. Declares First Quarter 2025 Common Share Dividend of U.S.$0.0650 (C$0.0934), and Declares First Quarter 2025 Preferred Share Dividends

Algonquin Power & Utilities Corp. Announces 2024 Fourth Quarter and Full Year Financial Results

Algonquin Power & Utilities Corp. Announces Extension of Cooperation Agreement with Starboard and Additions to the Board of Directors

Algonquin Power & Utilities Corp. Announces Date for First Quarter 2025 Financial Results and Conference Call

TSX:AQN

TSX:CTC

TSX:CTC.A

TSX:L

RBC Capital

Scotiabank

JP Morgan

CIBC

Wells Fargo

목요일(6일) CNN 머니 공포·탐욕 지수는 &#8220;극단적 공포&#8221; 영역에 머물렀다.
미국 증시는 목요일에 하락세로 마감했다. 다우존스 지수는 세션 중에 400포인트 이상 하락했다. 이는 미국이 캐나다, 멕시코, 중국 수입품에 관세를 부과하고 무역 파트너들이 미국 상품에 보복관세를 부과한 영향으로 나타났다.
크로거(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>)는 목요일에 4분기 실적이 예상치를 상회하는 실적을 발표했다.
경제지표 측면에서, 미국은 1월에 기록적인 1,314억 달러의 무역 적자를 발표했다. 이는 이전 달의 수정된 981억 달러 적자와 비교되는 수치다. 비농업 부문의 단위노동비용은 4분기에 2.2% 상승하여 초기 예상치 3% 상승과 차이를 보였다. 신규 실업수당 청구건수는 이전 주보다 21,000건 감소하여 2월 마지막 주에 221,000건이 되었으며, 시장 예상치 235,000건보다 적었다.
S&amp;P 500 지수 대부분의 섹터가 부정적으로 마감되었으며, 목요일에 부동산, 정보 기술 및 소비재 섹터가 가장 큰 손실을 기록했다. 그러나 에너지 섹터는 전반적인 시장 추세를 거스르며 세션을 상승세로 마감했다.
다우존스는 목요일에 약 428포인트 하락하여 42,579.08포인트로 마감했다. S&amp;P 500은 1.78% 하락하여 5,738.52포인트, 나스닥 종합지수는 2.61% 하락하여 18,069.26포인트로 마감했다.
투자자들은 오늘 알곤퀸 파워 앤 유틸리티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AQN#NYSE">AQN</a>), 제네스코(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCO#NYSE">GCO</a>), 어드밴티지 솔루션스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NYSE">ADV</a>)의 실적 결과를 기다리고 있다.
CNN 비즈니스 공포·탐욕 지수란?
공포·탐욕 지수는 현재 17.26로 목요일에 &#8220;극단적 공포&#8221; 영역에 머물렀다. 이전 수치는 17.29였다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 제공: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

트럼프 관세로 다우 지수 400p 하락: 탐욕 지수는 '극단적 공포' 유지

금요일(7일) 아침 미국 주식 선물이 상승하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 몇 가지 주식은 다음과 같다.
<ul>
<li>알곤퀸 파워 앤 유틸리티 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AQN#NYSE">AQN</a>): 월가가 주당 8센트의 분기 실적과 6억 7천만 달러의 매출을 예상하고 있다. 주가는 애프터마켓에서 1.3% 상승한 4.85달러를 기록했다.</li>
<li>제네스코 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCO#NYSE">GCO</a>): 금요일 개장 전 실적 발표 예정이다. 애널리스트들은 주당 3.31달러의 분기 실적과 7억 8,485만 달러의 매출을 기록할 것으로 예상하고 있다. 주가는 애프터마켓에서 0.2% 하락한 32.35달러로 거래되었다.</li>
<li>브로드컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>): 예상보다 나은 1분기 재무 실적을 발표했다. 회사는 2분기 매출이 약 149억 달러가 될 것으로 전망하며, 이는 147억 6천만 달러 예상치보다 높다. 또한 1분기 조정 EBITDA가 예상 매출의 약 66%가 될 것으로 예상하고 있다. 주가는 애프터마켓에서 12.8% 상승하여 202.45달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 보도</a>를 확인하세요.
<ul>
<li>스미스 앤 웨슨 브랜드 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>): 3분기 매출이 예상보다 저조하다고 발표했다. 테네시주 메리빌에 본사를 둔 이 회사는 분기 매출이 1억 1,590만 달러로, 1억 1,950만 달러의 예상치를 하회하며 2.99% 감소했다. 주가는 애프터마켓에서 8.1% 하락하여 10.13달러로 거래되었다.</li>
<li>어드밴티지 솔루션스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NYSE">ADV</a>): 애널리스트들은 주당 12센트의 분기 실적과 8억 6,341만 달러의 매출을 기록할 것으로 예상하고 있다. 주가는 애프터마켓에서 5.5% 상승하여 2.49달러에 거래되었다.</li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Algonquin Power

뉴스

에 대한 최신 뉴스 Algonquin Power (NYSE:AQN) 주식

금요일, 3월 07, 2025

뉴스

파트너 / 기고자

벤징가 글로벌